Adverse events (AEs) (1 or more events) · People with vascular dementia
It is very uncertain whether naoMaiTai changes adverse events (AEs) (1 or more events) compared with western medicine (very low certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · People with vascular dementia
NaoXinTong showed no clear difference in adverse events (AEs) (1 or more events) compared with western medicine (moderate certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · People with vascular dementia
ShenFuTang showed no clear difference in adverse events (AEs) (1 or more events) compared with western medicine (low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether cerebrospinal fluid filtration changes participants with 1 or more serious adverse events compared with plasma exchange (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
1 finding from 1 review
Participants with 1 or more serious adverse events · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Participants with one or more serious adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in participants with one or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Participants with at least some Side Effects · community‐dwelling older adults ≥ 65 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: number of people with 1 or more (all‐cause) · patients with chronic obstructive pulmonary disease
It is very uncertain whether multi‐component interventions (with telehealth as a component of care) changes adverse events: number of people with 1 or more (all‐cause) compared with usual care (very low certainty).
1 finding from 1 review
Intervention not reported
Serious Adverse Events (Participants with one or more event) · Adults (>18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)
It is very uncertain whether the intervention changes serious Adverse Events (Participants with one or more event) (very low certainty).
1 finding from 1 review
Serious adverse events (typically more serious complications) ( · children with displaced distal radius fracture with intact or involved or displaced ulna fracture (both‐bone fracture)
It is very uncertain whether summary of findings. Surgery (percutaneous wire fixation) changes serious adverse events (typically more serious complications) ( compared with not surgery (cast only) (very low certainty).
1 finding from 1 review
Proportion of participants with 1 or more serious adverse events · chronic hepatitis B
1 finding from 1 review
Proportion of participants with 1 or more serious adverse events · chronic hepatitis B
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events: participants incurring one or more adverse events · participants undergoing rehabilitation following surgery for flexor tendon injuries of the handa
1 finding from 1 review
Adverse events: participants incurring one or more adverse events · participants undergoing rehabilitation following surgery for flexor tendon injuries of the handa
1 finding from 1 review
Adverse events: participants incurring one or more adverse events · participants undergoing rehabilitation following surgery for flexor tendon injuries of the handa
It is very uncertain whether early active flexion plus controlled passive exercise regimen changes adverse events: participants incurring one or more adverse events compared with early controlled passive exercise regimen (very low certainty).
1 finding from 1 review
Proportion of participants with one or more serious adverse events · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes proportion of participants with one or more serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · People with vascular dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found